DHRSX

Across TCGA pan-cancer cohorts, DHRSX mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHRSX data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher DHRSX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHRSX expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

GBM, LSCC, and LUAD are the cancer types where DHRSX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.558	0.873	<.001	23	view →
LSCC	DFS	Median	II,III,IV	0.538	0.849	.006	13	view →
LUAD	OS	Tertile	II,III,IV	0.468	0.935	.005	13	view →
CCRCC	DFS	Tertile	III,IV	0.904	0.123	.024	6	view →
PDAC	OS	Median	II,III,IV	0.892	0.793	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHRSX–GBM (DFS)

Open the GBM breakdown →